Le Lézard
Classified in: Business
Subject: MISCELLANEOUS

AGF Reports May 2020 Assets Under Management


TORONTO, June 03, 2020 (GLOBE NEWSWIRE) -- AGF Management Limited reported total fee-earning assets under management (AUM) of $36.3 billion as at May 31, 2020. 

      
      
      
      
      
      
      
      
AUM

($ billions)
May 31,
2020
April 30,
2020
% Change
Month-Over-
Month
May 31,
2019
% Change
Year-Over-
Year
      
      
      
      
      
      
      
      
Total Mutual Fund (including retail pooled funds)$18.2$17.8 $18.7 
      
      
      
      
      
      
      
      
Institutional and Sub-advisory  +
High-net-worth + Exchange-traded funds
$15.2$15.6 $17.4 
      
      
      
      
      
      
      
      
Subtotal  
(before Private Alternative AUM)
$33.4$33.4 $36.1 
      
      
      
      
      
      
      
      
Private Alternative AUM$2.9$2.9 $2.2 
      
      
      
      
      
      
      
      
Total AUM $36.3$36.30.0%$38.3(5.2%)
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
Average Daily Mutual Fund AUM$17.8$17.3 $18.9 


Mutual Fund AUM by Category (including retail pooled funds)  

($ billions)
May 31,
2020
April 30,
2020
May 31,
2019
Domestic Equity Funds$3.3$3.3$3.4
U.S. and International Equity Funds8.27.98.3
Domestic Balanced Funds0.40.40.5
U.S. and International Balanced Funds1.41.31.2
Domestic Fixed Income Funds1.41.41.5
U.S. and International Fixed Income Funds3.33.33.7
Domestic Money Market0.20.20.1
Total Mutual Fund AUM$18.2$17.8$18.7

ABOUT AGF MANAGEMENT LIMITED

Founded in 1957, AGF Management Limited (AGF) is an independent and globally diverse asset management firm. AGF brings a disciplined approach to delivering excellence in investment management through its fundamental, quantitative, alternative and high-net-worth businesses focused on providing an exceptional client experience. AGF's suite of investment solutions extends globally to a wide range of clients, from financial advisors and individual investors to institutional investors including pension plans, corporate plans, sovereign wealth funds and endowments and foundations.

AGF has investment operations and client servicing teams on the ground in North America, Europe and Asia. With over $36 billion in total assets under management, AGF serves more than one million investors. AGF trades on the Toronto Stock Exchange under the symbol AGF.B.

AGF Management Limited shareholders, analysts and media, please contact:

Adrian Basaraba
Senior Vice-President and Chief Financial Officer
416-865-4203, [email protected]


These press releases may also interest you

at 18:15
Americas Gold and Silver Corporation ("Americas" or the "Company"), a growing North American precious metals producer, reports consolidated financial and operational results for the year ended December 31, 2023. This earnings release should be...

at 18:15
Westhaven Gold Corp. is pleased to announce that it has closed the final tranche of the non-brokered private placement announced on February 20, 2024. Westhaven has issued a total of 7,926,182 common shares that qualify as "flow-through shares" of...

at 18:03
Revenue Revenue for the year was $238.5, down $1.4 from sales of $239.9 in 2022. The Company's  sales were flat when compared to 2022 and 2021 included a fifteen month period due to the accounting change from September 30 to December 31. Twelve-month...

at 18:02
Buhler Industries Inc. ("Buhler Industries or the Company"), the manufacturer of Versatile and Farm King brands of farm equipment, has made operational restructuring changes in the first quarter of 2024 that is expected to result in significant full...

at 18:01
Buhler Versatile Inc. ("Versatile"), a wholly owned subsidiary of Buhler Industries Inc. (Buhler Industries or the Company), has received $14.4 million Canadian ($10.7 million USD) in additional long term financing from its majority owner Ba?ak...

at 18:00
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory University School of Medicine....



News published on and distributed by: